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We have constructed chimeric retroviral envelopes displaying N-terminal polypeptides that are known to form homotrimeric
associations. The amphotropic receptor (RAM-1) binding domain from the trimeric surface (SU) glycoprotein of 4070A
murine leukemia virus (MLV)-inhibited ecotropic receptor (Rec-1) mediated infection by the SU glycoprotein of Moloney
MLV when grafted to its N-terminus. The block to Rec-1-mediated infection was reversed when the RAM-1 binding domain
was cleaved from the vector particles using an engineered factor Xa protease-sensitive cleavage signal between the
envelope glycoprotein and its N-terminal extension. Trimeric leucine zipper peptides and the trimeric C-terminal domain of
CD40 ligand were shown to inhibit RAM-1-mediated infection of NIH3T3 cells by the 4070A envelope when fused to its N-
terminus, whereas monomeric helical peptides and the monomeric epidermal growth factor domain did not. The block to
RAM-1-mediated infection was reversed when the trimeric polypeptides were cleaved from the vector particles by addition
of factor Xa protease. Envelope binding assays using cleaved and uncleaved chimeric 4070A envelopes revealed that
binding to RAM-1 receptors on mammalian cells was hindered by trimeric, but not by monomeric, N-terminal polypeptides.
These results have important implications for the design of protease-activatable vectors for targeted gene delivery. q 1997
Academic Press
INTRODUCTION We have been exploring different strategies for tar-
geting the entry of retroviral vectors into selected target
MLV-derived retroviral vectors are versatile gene deliv- cells by engineering new determinants into their SU gly-
ery vehicles whose host range properties are determined coproteins (Cosset et al., 1995a; Nilson et al., 1996; Rus-
by membrane glycoproteins which mediate their attach- sell et al., 1993; Valsesia-Wittmann et al., 1994, 1996).
ment to specific receptors and subsequently trigger fu- We previously observed that displayed polypeptides can
sion. The envelope glycoproteins of the murine leukemia interfere with retroviral entry by sequestering the vector
virus (MLV) are displayed as a homotrimeric complex on particles onto cell surface receptors that do not support
the surface of the virus (Fass et al., 1996; Kamps et al., the subsequent steps in retrovirus entry (Cosset et al.,
1991). Each subunit of the trimer consists of two parts, 1995a; Nilson et al., 1996). This work provided the basis
SU and TM. The SU (surface) component is entirely ex- for the construction of EGF receptor-targeted vectors
traviral and is attached to the retrovirus via the smaller whose infectivity could be activated by disease-associ-
TM (transmembrane) component, which anchors the ated matrix metalloproteinases (Peng et al., 1997). One
complex in the viral membrane (Pinter et al., 1978). The N- weakness of this two-step targeting strategy is a high
terminal domain of the SU glycoprotein confers receptor level of residual infectivity on nontarget cells because
specificity and exhibits a high degree of conservation the cleavable binding domain does not completely block
between MLVs with different host ranges (Battini et al., the ability of the SU trimer to attach to its natural Ram-
1995). Moloney MLV envelopes confer an ecotropic host 1 receptor. We have therefore elucidated an alternative
range because they bind to a murine cationic amino mechanism by which (trimerizing) polypeptides can inter-
acid transporter (Albritton et al., 1993, 1989). 4070A MLV fere with the infectivity of retroviral vectors when dis-
envelopes attach to the RAM-1 phosphate transporter, played as N-terminal extensions of the envelope glyco-
which is conserved throughout many mammalian spe- protein, by sterically blocking virus attachment to the
cies, to confer an amphotropic host range (Kavanaugh Ram-1 receptor. Our results have important implications
et al., 1994). After binding to target cell receptors has for the improved design of protease-activatable retroviral
occurred, the trimeric SU–TM complex is thought to un- vectors.
dergo a large conformational rearrangement that triggers In preliminary experiments designed to characterize
the process of fusion between the viral and target cell the ecotropic infectivity of Moloney MLV envelope chime-
membranes. ras, it was found that a vector displaying the Ram-1-
targeted AXMo1 envelope (Nilson et al., 1996), could not
efficiently infect cells through the ecotropic receptor1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 01223 402140. (Rec-1) unless it was first cleaved by factor Xa protease.
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A possible explanation for this property of the AXMo1 PCR fragments by priming off each other and then outer
primers Gal4back and Gal4for were used to amplify theenvelope was that the displayed RAM-1 binding domain
might be forming a trimeric complex at the tip of the fragments further. The PCR products were digested with
SfiI and NotI and cloned into the SfiI/NotI-digested back-Moloney SU glycoprotein trimer to which it was grafted,
thereby blocking its Rec-1 binding site. To further test bones of EXA1, pEGS1XA1, and pEGS3XA1. The correct
sequence of all constructs was verified by DNA sequenc-the idea that homo-oligomerization of a displayed poly-
peptide might block receptor attachment by the underly- ing. Oligonucleotides used, with restriction sites under-
lined: NotGS1XA1back, 5*-GCA AAT CTG CGG CCG CAGing envelope, we grafted oligomerizing leucine zipper
peptides (Harbury et al., 1993) and the trimeric C-terminal GTG GAG GCG GTT CAA TCG AGG GAA GGA TGG CAG
AG-3*; NotGS3XA1back, 5*-GCA AAT CTG CGG CCGextracellular domain of CD40 ligand (Karpusas et al.,
1995) onto 4070A SU glycoproteins and characterized the CAG GTG GAG GCG GTT CAG GCG GAG GTG GCT CTG
GCG GTG GCG GAT CGA TCG AGG GAA GAA TGG CAGproperties of retroviral vectors incorporating the chimeric
envelopes. AG-3*; 4070Afor, 5*-CTG CAA GCC CAC ATT GTT CC-3*;
Gal4 VLback (containing SfiI site), 5*-GGC ATT CAT GCG
GCC GCG GCC CAG CCG GCC ATG AAG CAA CTA GAAMATERIALS AND METHODS
GAC AAG GTG GAG GAA CTC CTT AGC AAG GTA TAC
Plasmid construction
C-3*; Gal4 VLfor (containing NotI site), 5*-GCA AAT CTG
CGG CCG CCT CTC CAA CAA GCT TCT TCA GTC GAGThe unmodified envelopes of 4070A MLV and Moloney
MLV were encoded by the expression plasmids FB40- CGA CTT CGT TCT CAA GAT GGT ATA CCT TGC TAA
GGA G-3*; Gal4 AAback (containing SfiI site), 5*-GGC70ASALF (A) and FBMoSALF (Mo), respectively (Cosset
et al., 1995b). The constructs AMo1 and AXMo1, which ATT CAT GCG GCC GCG GCC CAG CCG GCC ATG AAG
CAA GCA GAA GAC AAG GCA GAG GAA GCT CTT AGCcode for chimeric envelopes in which the RAM-1 receptor
binding domain from 4070A SU is fused to amino acid AAG GCT TAC C-3*; Gal4 AAfor (containing NotI site), 5*-
GCA AAT CTG CGG CCG CCT CTC CAG CAA GCT TCT/1 of Moloney SU by a factor Xa protease-cleavable
(AAAIEGR) or noncleavable (AAA) linker have been de- TTG CTC GAG CAG CTT CGT TCT CTG CAT GGT AAG
CCT TGC TAA GAG C-3*; Gal4 IIback (containing SfiIscribed previously (Nilson et al., 1996). Constructs, EA1
and EXA1, coding for chimeric envelopes in which EGF site), 5*-GGC ATT CAT GCG GCC GCG GCC CAG CCG
GCC ATG AAG CAA ATC GAA GAC AAG ATA GAG GAAis fused to amino acid /1 of 4070A SU by a linker com-
prising three alanines, or three alanines and the IEGR ATT CTT AGC AAG ATC TAC C-3*; Gal4 IIfor (containing
NotI site), 5*-GCA AAT CTG CGG CCG CCT CTC CTAfactor Xa cleavage site, have also been described (Nilson
et al., 1996). TAA GCT TCT TGA TTC GAG CAA TTT CGT TCT CTA
TAT GGT AGA TCT TGC TAA GAA TTT C-3*; Gal4 back,To construct vectors displaying helical peptides, plas-
mids pEGS1XA1 and pEGS3XA1 were first produced 5*-GGC ATT CAT GCG GCC GCG GC-3*; Gal4 for, 5*-
GCA AAT CTG CGG CCG CCT CTC-3*.where there is a 12-amino acid (AAAGGGGSIEGR) or
22-amino acid (AAAGGGGSGGGGSGGGGSIEGR) linker, To generate the plasmid pCD40LXA1 PCR primers
CD40Lback and CD40Lfor were used to amplify the solu-respectively, between the 4070A MLV envelope and the
displayed EGF domain. PCR primers NotGS1XA1back ble C-terminal extracellular domain of the trimeric human
CD40 ligand (146 amino acids—residues 116 to 261)and NotGS3XA1back (respectively) were used with
primer 4070Afor to amplify modified envelope fragments from a cDNA template (ATCC 79813). The PCR product
was digested with SfiI and NotI and cloned into the SfiI/from EXA1 which were digested with NotI and BamHI
and cloned into the NotI/BamHI-digested backbone of NotI-digested backbone of EXA1. Again the correct se-
quence was verified by DNA sequencing. Oligonucleo-EA1. To generate plasmids pVLXA1, pVLGS1XA1, and
pVLGS3XA1, PCR primers Gal4 VLback and Gal4 VLfor tides used, with restriction sites underlined: CD40Lback
(containing SfiI site), 5*-CCG GTA CCG GCC CAG CCGwere used to produce PCR fragments by priming off each
other and then outer primers Gal4back and Gal4for were GCC GGT GAT CAG AAT CCT CAA ATT GC-3*; CD40Lfor
(containing NotI site), 5*-AAG TCT TAG CGG CCG CGAused to amplify the fragment further. The PCR products
were digested with SfiI and NotI and cloned into the GTT TGA GTA AGC CAA AGG-3*
SfiI/NotI-digested backbones of EXA1, pEGS1XA1, and
pEGS3XA1. To generate plasmids pAAXA1 and pAAG- Target cell lines and production of viruses
S3XA1, PCR primers Gal4 AAback and Gal4 AAfor were
used to produce PCR fragments by priming off each other GP / Env AM12 cells (Markowitz et al., 1988) were
derived from the murine cell line, NIH 3T3, and expressand then outer primers Gal4back and Gal4for were used
to amplify the fragments further. The PCR products were the MLV-A envelope which blocks the RAM-1 receptor
by interference. NIH 3T3, GP / Env AM12, and the hu-digested with SfiI and NotI and cloned into the SfiI/NotI-
digested backbones of EXA1 and pEGS3XA1. To gener- man cell line, A431 (Giard et al., 1973), were grown in
DMEM supplemented with 10% fetal calf serum. Cear13ate plasmids pIIXA1, pIIGS1XA1, and pIIGS3XA1 PCR
primers Gal4 IIback and Gal4 IIfor were used to produce (Kozak et al., 1995) were grown in DMEM supplemented
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with 10% fetal calf serum and proline (Life-Technologies). galactosidase activity was performed as previously de-
scribed (Takeuchi et al., 1994). Viral titer (enzyme formingThe different envelope expression constructs were trans-
fected into TELCeB6 packaging cells (Cosset et al., units/ml) was calculated by counting blue stained colo-
nies microscopically with the use of a grid placed under-1995b) by calcium phosphate precipitation (Sambrook
et al., 1989) and stable phleomycin (50 mg/ml)-resistant neath the 6-well plates.
colonies were expanded and pooled. Cells were grown
in DMEM supplemented with 10% fetal calf serum and Binding assays
when confluent transferred from 377 to 327 and incubated
The viral supernatants to be analyzed were incubatedfor 72 hr. Supernatants containing retroviral particles
with 0 or 4 mg/ml of Factor Xa for 90 min at 377. The targetwere harvested after overnight (16 hr) incubation at 327
cells were washed in PBS and detached by incubation atin 10 ml serum-free DMEM for infections, or DMEM sup-
377 in 0.5 mM EDTA (pH 7.2). Cells were washed withplemented with 2% fetal calf serum for immunoblots and
PBS containing 2% BSA and approximately 5 1 105 cellsbinding assays. All supernatants were filtered (0.45 mm)
were incubated with the treated viral supernatants for 1before use.
hr at 377. Cells were then washed with PBS/2% BSA
and incubated with 83A25 monoclonal antibodies raisedImmunoblots
against the MLV SU (Evans et al., 1990) for 1 hr at 47. Cells
To obtain cell lysates, virus producer cells were lysed were washed with PBS/2% BSA again and incubated with
in a 20 mM Tris–HCl buffer (pH 7.5) containing 1% Triton anti-rat IgG FITC-conjugated antibodies (DAKO, UK) for
X-100, 0.05% SDS, 5 mg/ml sodium deoxycholate, 150 1 hr at 47. Before the final wash in PBS/2% BSA, cells
mM NaCl, and 1 mM phenylmethylsulfonylfluoride. Ly- were counter-stained with 20 mg/ml propidium iodide.
sates were incubated for 10 min at 47 and then centri- Fluorescence of living cells was then analyzed with a
fuged for 10 min at 10,000g to pellet the unwanted nuclei. fluorescence-activated cell sorter (FACSCalibur, Beck-
Virus samples were obtained by ultracentrifugation of ton-Dickinson).
filtered viral supernatants (10 ml) at 30,000 rpm in a SW40
rotor (Beckman, U.S.A.) for 1 hr at 47. The pelleted viral RESULTS
particles were resuspended in 100 ml cold PBS. Samples
Rec-1-mediated infection by envelopes expressing a(30 ml for cell lysates or 10 ml for pelleted virions) were
Ram-1 targeting domainthen separated on a 10% polyacrylamide gel under reduc-
ing conditions followed by transfer of the proteins onto
AMo1 and AXMo1 are previously described chimeric
nitrocellulose paper. For Factor Xa cleavage, 10 ml of the
envelopes in which the RAM-1 receptor binding domain
pelleted viral particles was incubated with 0 or 4 mg/ml
from 4070A SU is fused to amino acid /1 of Moloney
of Factor Xa (Promega, U.S.A.) for 90 min at 377 in the
SU by a noncleavable (AAA) or factor Xa-cleavable (AAA-
presence of 2.5 mM CaCl2 before running on the separat- IEGR) linker (Nilson et al., 1996). It was previously shown
ing gel. The SU proteins were detected as previously
that these chimeric envelopes were incorporated into
described (Cosset et al., 1995a) using specific goat anti-
virions with equal efficiency (although less efficiently
bodies raised against either Rausher leukemia virus
than the unmodified Moloney SU) and that AXMo1, but
(RLV) gp70 SU or RLV p30 capsid protein (CA) (Quality
not AMo1 envelopes, were cleaved by factor Xa protease
Biotech, Inc., U.S.A.) which were diluted 1/1,000 and 1/
to yield an SU cleavage product whose mobility was
10,000, respectively. Blots were developed with horse-
indistinguishable from unmodified Mo SU (Nilson et al.,
radish peroxidase-conjugated rabbit anti-goat antibodies
1996).
(DAKO, Denmark) and an enhanced chemiluminescence
The infectivity of these Ram-1-targeted vectors was
kit (Amersham Life Science, UK).
then tested on NIH3T3 cells and on NIH3T3 transfectants
(GP / Env AM12) overexpressing the 4070A envelopeTarget cell infection
which blocks the corresponding Ram-1 receptor by inter-
ference. The vectors AMo1 and AXMo1 were fully infec-Target cells were seeded at 2 1 105 cells/well in six-
well plates and incubated at 377 overnight. Producer cell tious on the unmodified NIH3T3 cells which express both
Rec-1 and Ram-1, giving titers in excess of 106 efu persupernatants containing b-galactosidase-transducing
retroviruses were filtered (0.45 mm) after overnight incu- ml (not shown); however, their infectivity was greatly re-
duced on the Ram-1-deficient cells, suggesting that theybation at 327 in serum-free medium. The harvested super-
natants were incubated with 0 or 4 mg/ml of factor Xa were unable to utilize the ecotropic receptor, Rec-1 (Fig.
1). This result was unexpected and was in contrast to(Promega) for 90 min at 377 in the presence of 2.5 mM
CaCl2 . Supernatant dilutions in 2 ml serum-free media results obtained with similar chimeric Moloney SU glyco-
proteins displaying monomeric growth factor domains orwere incubated with target cells for 6 hr in the presence
of 8 mg/ml polybrene. The retroviral supernatant was then single chain antibody fragments in which Rec-1-medi-
ated infection was not seriously compromised by theremoved and the cells were incubated with regular me-
dium for 48–72 hr. X-Gal staining for detection of b- displayed domains (Ager et al., 1996; Cosset et al.,
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comprising amino acids AAAIEGR, AAAGGGGSIEGR, or
AAAGGGGSGGGGSGGGGSIEGR, where the highlighted
sequence is known to be recognized and cleaved by Factor
Xa (Nilson et al., 1996).
Expression, viral incorporation, and cleavage of
chimeric 4070A envelopes
The AA, VL, and II chimeric envelopes and a control
amphotropic (4070A) envelope were stably transfected
into TELCeB6 cells which express MLV gag-pol core par-
ticles and an nls LacZ retroviral vector (Cosset et al.,
1995b). Virus-containing supernatants were harvested
from these stably transfected TELCeB6 cells and ultra-
centrifuged to pellet the viral particles. Pellets were than
analyzed on immunoblots for the presence of viral coreFIG. 1. Reversible inhibition of infection by cleavage of chimeric
envelopes expressing a factor Xa-cleavable, N-terminal RAM-1 bind- proteins and envelope proteins (Fig. 3A). The number of
ing domain. The target cell line GP / Env AM12 was infected with vector particles present in each sample, determined by
harvested producer cell supernatants containing b-galactosidase- staining with p30 antiserum to detect the p30 CA protein,
transducing retroviruses (AMo1, AXMo1, Mo, and A) before (0) or after
was found to be approximately equivalent. However,(/) treatment with factor Xa protease. Detection of b-galactosidase
when the efficiencies of viral incorporation of the differentactivity was performed by X-gal staining and titers were expressed
as e.f.u./ml. chimeric envelopes were compared, by staining with an
anti-SU antiserum, it was found that incorporation is
greatly influenced by the presence of the oligomerizing
1995a). This led to the proposal that the displayed Ram- peptide. Envelopes displaying the control monomeric
1 binding domain might be forming a trimeric complex peptide (AA) were incorporated almost as efficiently as
at the tip of the Moloney SU glycoprotein trimer to which wild-type 4070A envelopes, whereas envelopes dis-
it was grafted, thereby blocking the Rec-1 binding site playing the VL peptide were incorporated much less effi-
and/or interfering with Rec-1-mediated fusion triggering. ciently and there was no visible incorporation of enve-
Such a block would be expected to be reversible by lopes displaying the II peptide. To determine if the helical
cleaving the Ram-1 binding domain from the vector and, peptides could be cleaved from the SU glycoproteins to
in keeping with this prediction, the infectivity of the which they were grafted, viral pellets were digested with
AXMo1 vector was fully restored on Rec-1-positive, Ram- 0 or 4 mg/ml factor Xa protease and then analyzed on
1-deficient cells when the Ram-1 targeting domain was immunoblots as before. Figure 3B shows that there is a
cleaved from its surface with factor Xa protease (Fig. 1). mobility shift when expressed envelopes VLXA1, AAXA1,
and the control, EXA1, have been cleaved with factor Xa
Construction of chimeric 4070A envelopes displaying protease, indicating that the helical peptides are indeed
helical peptides cleaved from the SU. Due to the low levels of incorpora-
tion of the IIXA1 chimeric envelope, cleavage cannot beTo further test the idea that a trimeric polypeptide could
seen for this vector. This immunoblot also indicates thatblock the functions of a trimeric envelope glycoprotein
the chimeric envelope AAXA1 was incorporated 10 timeswhen fused to its N-terminus, and to determine whether
more efficiently than VLXA1.the concept could be applied to an amphotropic MLV SU
To further investigate the poor incorporation of the VLglycoprotein, we made a series of constructs coding for
and II chimeric envelopes we performed immunoblots ofchimeric envelopes in which monomeric or trimerizing heli-
cell lysates prepared from the virus producing TELCeB6cal peptides were fused to amino acid /1 of 4070A SU via
transfectants. Figure 3C shows that the unprocessed pre-Factor Xa-cleavable linkers (Fig. 2). The helical peptides
cursors of all three chimeric envelopes are detectable inthat were chosen for these studies were variants of the
the cell lysates. However, the VL and II envelope precur-dimeric GCN4 leucine zipper peptide with systematic V, L,
sors are less abundant than the AA precursor. Also, theI, or A (single letter amino acid code) substitutions in the
processing of the VL and II precursors to mature SU isa and d positions of the heptad repeat that are known to
severely impaired relative to the processing of the AA
force the formation of trimeric coiled coils (VL and II pep-
precursor, indicating that these chimeric envelopes are
tides) or to prevent oligomerization (AA peptide) (Harbury
not efficiently transported from the endoplasmic reticu-
et al., 1993). When designing these constructs, we were
lum to the Golgi compartment.
concerned that the oligomerization of the displayed VL and
Infectivity of vectors displaying chimeric envelopesII peptides might be hindered if they were tethered too
before and after cleavageclosely to the underlying 4070A SU glycoprotein. The spac-
ing between the 4070A SU glycoprotein and the displayed To determine whether the helical peptides were mask-
ing the functions of the 4070A envelopes to which theypeptide motifs was therefore varied by insertion of linkers
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FIG. 2. Diagrammatic representation of plasmid constructs coding for chimeric envelope glycoproteins in which the helical peptides AA, VL, and
II were fused to residue /1 of the 4070A MLV SU. The general format is shown diagrammatically and the amino acid sequence (single-letter code)
of the helical peptides and the linkers between these peptides and the SU protein are shown in detail. LTR, long terminal repeat; L, envelope signal
peptide. Amino acid residues at the a and d positions of the heptad repeat are shown in bold.
were fused we titrated the vectors on Ram-1 expressing Chimeric 4070A envelopes displaying the CD40
ligandcells, NIH3T3 and A431, before and after they were
cleaved with factor Xa protease (Table 1 and Fig. 4).
In an attempt to overcome the poor incorporationThe control vectors displaying the AA peptide gave titers
shown by the VL and II chimeric envelopes we wentcomparable to that of the wild-type amphotropic vector
on to study chimeric envelopes displaying the solubleand the titers did not change after factor Xa cleavage,
extracellular C-terminal domain of human CD40 ligandindicating that the AA peptide does not significantly inter-
(residues 116 to 261) which is known to fold as a sand-fere with the functions of the underlying 4070A envelope.
wich of two b-sheets with jellyroll topology before as-Conversely, the vectors displaying the trimerizing VL and
sembling into a stable homotrimer with the shape of aII helical peptides gave greatly reduced titers on both
truncated pyramid (Karpusas et al., 1995). The rationalecell lines which were enhanced as much as 2000-fold
for choosing CD40 ligand was based on the hypothesisby factor Xa cleavage. In the case of the VLXA1 chimeric
that the low intracellular abundance of the VL and IIenvelope, on cleavage with 4 mg/ml factor Xa protease,
chimeric envelopes might have been due to prematurethe titer on NIH3T3 cells increased from 151 efu/ml to 3
oligomerization of the nascent polypeptide chains via1 105 efu/ml and on A431 cells from 318 efu/ml to 105
their N-terminal peptide extensions (see discussion). Itefu/ml (Fig. 4). Vectors displaying the II helical peptide
was reasoned that the C-terminal domain of CD40 ligandgave generally lower titers than those displaying the VL
would be less likely to direct premature oligomerizationpeptide, presumably due to the reduced incorporation of
of the chimeric envelopes because of the time requiredchimeric envelopes displaying the II peptide. Interdomain
for correct chaperone-guided folding of the domain as aspacing had little apparent influence on the titer of the
prelude to its assembly into a stable trimeric complex.uncleaved vectors, nor on the degree of titer enhance-
We therefore made the construct, CD40LXA1, whichment that was observed after exposure to the factor Xa
protease. codes for a chimeric envelope in which the trimeric C-
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FIG. 3. Viral incorporation and cleavage of chimeric envelopes expressing factor Xa-cleavable helical peptides as N-terminal extensions of the
4070A MLV SU. (A) Immunoblot of pelleted retroviral particles incorporating chimeric envelopes: 1. VLXA1 2. VLGS1XA1 3. VLGS3XA1 4. AAXA1 5.
AAGS3XA1 6. IIXA1 7. IIGS1XA1 8. IIGS3XA1 9. A. The top immunoblot was probed with an anti-SU antiserum and the lower one with an anti-p30
antiserum to detect the p30 CA protein. (B) Factor Xa-mediated cleavage of chimeric envelopes. Immunoblot of pelleted recombinant amphotropic
retroviral particles incorporating A, VLXA1, AAXA1, IIXA1, or EXA1 envelopes before (0) or after (/) treatment with factor Xa protease, probed with
anti-SU antiserum. (C) Immunoblot of cell lysates prepared from the virus producing TELCeB6 transfectants A, VLXA1, AAXA1, IIXA1, and the control,
untransfected TELCeB6, probed with anti-SU antiserum.
terminal domain of CD40 ligand was fused to amino acid the CD40LXA1 envelope compares favorably with the
incorporation of VLXA1 and IIXA1 envelopes which were/1 of 4070A SU via a Factor Xa-cleavable linker (AAA-
IEGR). For characterization of the CD40LXA1 envelope, (respectively) 2 and less than 0.5% of wild-type incorpora-
tion (Fig. 3B). The CD40LXA1 and EXA1 envelopeswe used a previously described control chimeric enve-
lope (EXA1) displaying a factor Xa-cleavable monomeric showed the expected mobility shift on immunoblots upon
cleavage with 4 mg/ml factor Xa protease, indicating thatEGF domain fused to amino acid /1 of the 4070A SU.
The CD40LXA1 and EXA1 chimeric envelopes and the the displayed domains were indeed cleaved from the SU
(data not shown).control unmodified 4070A envelope were stably ex-
pressed in TELCeB6 cells. Virus-containing supernatants To determine whether the displayed trimeric C-termi-
nal domain of CD40 ligand was masking the functionswere harvested from the transfected cells, ultracentri-
fuged to pellet the viral particles, and the pellets were of the 4070A envelope the vectors were titrated on Ram-
1-expressing NIH3T3 cells before and after they wereanalyzed on immunoblots for the presence of envelope
proteins. By comparison of band intensities on immu- cleaved with factor Xa protease. In keeping with expecta-
tions, the vectors displaying the C-terminal domain ofnoblots it was estimated that viral incorporation of the
CD40LXA1 and EXA1 envelopes were (respectively) 10 CD40 ligand gave a low background infectivity on NIH3T3
cells (2 1 103 efu/ml), which increased by more thanand 50% of wild-type 4070A envelope incorporation (data
not shown). The 10% figure for relative incorporation of three logs to 4 1 106 efu/ml after the virus was cleaved
TABLE 1
Reversible Inhibition of Infection by Cleavage of Chimeric Envelopes Expressing a Factor Xa-Cleavable, N-Terminal Oligomerizing Peptide
Titer (e.f.u./ml) of harvested b-galactosidase-transducing retroviruses
A AAXA1 AAGS3X1 VLXA1 VLGS1XA1 VLGS3XA1 IIXA1 IIGS1XA1 IIGS3XA1
Factor
Xaa 0 / 0 / 0 / 0 / 0 / 0 / 0 / 0 / 0 /
NIH3T3 107 107 2 1 106 2 1 106 2 1 106 2 1 106 151 3 1 105 5 1 103 2 1 104 2 1 104 3 1 105 6 103 34 103 103 8 1 103
A431 107 107 2 1 106 2 1 106 2 1 106 2 1 106 318 105 103 5 1 104 103 3 1 105 10 103 16 6 1 102 162 104
a Harvested producer cell supernatants containing b-galactosidase-transducing retroviruses were preincubated with (0) or without (/) factor Xa
protease.
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FIG. 4. Reversible inhibition of infection by cleavage of the chimeric envelope, VLXA1, expressing a factor Xa-cleavable, N-terminal oligomerizing
peptide. Magnified view of virally infected cells after X-gal staining. Chimeric envelope VLXA1 shows strong inhibition of infectivity on NIH 3T3 and
A431 cells, which is reversible on addition of factor Xa.
FIG. 5. Protease-dependent activation of infectivity of retroviral vectors displaying chimeric envelopes VLXA1.1 and CD40LXA1.9 expressing factor
Xa-cleavable, N-terminal trimeric polypeptides. Unmagnified view of NIH3T3 cells which were stained with X-gal substrate 72 hr after they were
infected with 1 ml of the indicated vector-containing supernatants, either uncleaved or cleaved by incubation with 4 mg/ml of factor Xa protease.
Chimeric envelopes displaying trimeric N-terminal domains show strong inhibition of infectivity which is reversible upon addition of factor Xa
protease, compared to chimeric envelopes displaying monomeric domains which show no inhibition of infection.
57
AID VY 8628 / 6a3b$$8628 06-25-97 14:15:13 viral AP: VY
58 MORLING ET AL.
with factor Xa protease. In line with our previous observa- AAXA1 and EXA1 chimeric envelopes which display mo-
nomeric N-terminal polypeptides. In contrast, the VLXA1tions on NIH3T3 cells (Cosset et al., 1995a) the control
vector displaying the monomeric EGF domain gave a and CD40LXA1 envelopes showed reduced RAM-1 bind-
ing to Cear13 cells in their uncleaved state but the bind-titer (2 1 106 efu/ml) comparable to that of the wild-type
amphotropic vector and the titer did not change after ing signal was significantly enhanced after they had been
cleaved by factor Xa protease. These results give strongfactor Xa cleavage, indicating that display of this mono-
meric peptide does not significantly interfere with the support to the hypothesis that the trimeric polypeptides
are blocking virus infectivity by masking receptor attach-functions of the underlying 4070A envelope [this is in
contrast to the situation on human cell lines expressing a ment sites of the SU glycoprotein to which they are
grafted.high density of EGF receptors where the EGF-displaying
vectors are competitively sequestered onto the EGF re-
ceptors leading to a drastic reduction in virus titer (Cos- DISCUSSION
set et al., 1995a; Nilson et al., 1996)].
In this report we have demonstrated reversible inhibi-
tion of retroviral vector attachment and infectivity by chi-Envelope binding assays to determine the mechanism
meric envelope glycoproteins displaying N-terminal poly-by which trimeric polypeptides block virus infection
peptides which are known to assemble into homotrimers.
The VL, II, and AA peptides that we fused to the 4070AWe next sought to determine the mechanism by which
the trimerizing polypeptides were blocking the function envelope are mutants of the GCN4 leucine zipper in
which the conserved, buried residues that direct the pro-of the envelope glycoproteins to which they were grafted.
One possibility was that the displayed polypeptides cess of oligomerization have been substituted with va-
line, leucine, isoleucine, or alanine residues (Harbury etmight be masking the binding of the underlying 4070A
SU to its receptor, RAM-1, by forming a trimeric complex al., 1993). The VL mutant oligomerizes to form extremely
stable (Tm 957) two- and three-stranded alpha-helicalat the tip of the SU glycoprotein trimer. Alternatively, it
could be that attachment to RAM-1 proceeds normally, coiled coil structures, whereas the II mutant forms exclu-
sively three-stranded coiled coils which are even morebut the N-terminal trimeric domain might sterically hinder
conformational rearrangements of the trimeric SU/TM stable (Tm  1007) than the VL structures. In the AA
peptide, all of the hydrophobic core residues of the GCN4complex involved in fusion. In order to discriminate be-
tween the two possibilities SU binding assays were car- leucine zipper were substituted with alanines to prevent
oligomerization of the mutant peptide while preservingried out on Cear13-transfected hamster cells that ex-
press the RAM-1 receptor (Kozak et al., 1995). its helical structure.
Retroviral incorporation of chimeric envelopes dis-Due to the low incorporation of the VLXA1 chimera,
binding assays using cleaved and uncleaved virus-con- playing the VL and II peptides was significantly impaired
relative to chimeric envelopes displaying the control AAtaining supernatants harvested from the pooled VLXA1
transfectants were initially uninformative. The VLXA1 and peptide, which showed only a slight reduction in incorpo-
ration compared to unmodified 4070A envelopes. TheCD40LXA1 plasmids were therefore retransfected into
TELCeB6 packaging cells and multiple single cell clones VL chimeric envelopes were approximately 10-fold less
abundant in viral pellets than the AA chimeric envelopes,were screened to isolate stable transfectants releasing
vector particles with higher levels of incorporation of the and the II chimeric envelopes were so poorly incorpo-
rated that they were not visible on immunoblots of pel-chimeric envelopes. Clones VLXA1.1 and CD40LXA1.9
were selected for further study since they gave, respec- leted virions. By immunoblotting cell lysates from the
transfected TELCeB6 cells with anti-envelope antiserum,tively, five- and twofold higher envelope incorporation
than supernatants from the corresponding pooled it was shown that the intracellular abundance of the pre-
cursor polypeptides for each of the chimeric envelopestransfectants (data not shown). Supernatants from these
clones (and control supernatants from AAXA1, EXA1, and was closely correlated with their abundance in viral pel-
lets. The low viral incorporation of the VL and II chimeric4070A transfectants) were titrated on NIH3T3 cells to
confirm that they exhibited the expected protease-depen- envelopes is therefore a consequence of their poor ex-
pression and/or folding in the virus-producing cells. Nei-dent activation of infectivity (Fig. 5).
Binding assays were then performed by incubating ther protein appears to be toxic to the virus producing
cells since there was no difference in the number or sizeCear13 target cells with cleaved or uncleaved virus su-
pernatants corresponding to the supernatants that were of stably transduced TELCeB6 clones that were ob-
tained after transfecting the different (oligomerizing orused for the infection assay shown in Fig. 5, and binding
of viral envelopes to the cell surface was analyzed by control) chimeric envelope expression plasmids (data not
shown). The low intracellular abundance of the VL andFACS analysis using 83A25 monoclonal antibodies
raised against the MLV SU (Fig. 6). RAM-1 binding was II envelope precursors might be a consequence of their
premature oligomerization in the endoplasmic reticulum.efficient and was unaffected by the addition of factor Xa
protease for the control 4070A envelope and for the Premature oligomerization of the nascent polypeptide
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FIG. 6. RAM-1 envelope binding assays using Cear13 cells as targets. The envelope glycoprotein content of the different samples was normalized
by comparing incorporation and expression on immunoblots. Background fluorescence was provided by incubating cells with DMEM only (no env).
Binding assays were performed with the chimeric envelopes using wild-type 4070A envelope as the positive control. Assays compare binding of
envelopes preincubated with 0 (white histograms) or 4 mg/ml (black histograms) of factor Xa protease.
chains via their N-terminal VL or II peptides could com- control AA chimeric envelopes displaying a nonoligo-
merizing helical peptide.promise the folding of individual subunits leading to their
aggregation and accelerated proteolytic destruction. In RAM-1-specific envelope binding assays using the
4070A chimeric envelopes gave strong support to thekeeping with this idea, in a related system the chaper-
one-guided folding of influenza haemagglutinin mono- notion that the trimerizing polypeptides are able to hin-
der virus attachment to RAM-1. Binding of the chimericmers is known to be completed in the endoplasmic retic-
ulum before the fully folded subunits can be assembled envelopes displaying monomeric (EGF and AA) poly-
peptides was unhindered and unaffected by cleavageinto homotrimers (Tatu et al., 1995). The fact that the II
helical peptide forms very stable trimers and that the of the displayed domains. In contrast, RAM-1 binding
of chimeric envelopes displaying the trimeric (CD40LVL peptide forms slightly weaker interactions might then
explain why the chimeric envelopes displaying the VL and VL) polypeptides was reduced. However, when fac-
tor Xa protease was used to cleave the trimeric polypep-peptides gave better incorporation than the chimeric en-
velopes displaying the II peptides. To overcome these tides from the chimeric envelopes, binding capacities
were restored. The CD40 ligand domain seemed to bepotential problems we displayed the soluble extracellular
domain of the trimeric CD40 ligand on the 4070A enve- more efficient at blocking binding than the short VL
peptide, perhaps because it is a considerably largerlope. It was reasoned that the C-terminal domain of CD40
ligand would be unlikely to direct premature oligomeriza- domain. From these binding assays it is clear that im-
paired receptor attachment is an important mechanismtion of the chimeric envelopes because its assembly into
a stable trimeric complex would be delayed until correct whereby the trimeric polypeptides inhibit virus infectiv-
ity. However, it is not possible to exclude that an addi-folding of the domain was completed, probably under the
guidance of cellular chaperone proteins. In keeping with tional mechanism of inhibition could be operating in
these chimeric envelopes whereby the N-terminal tri-this prediction, viral incorporation of chimeric envelopes
displaying the CD40 ligand domain was fivefold more meric domain is sterically hindering conformational re-
arrangements of the trimeric SU/TM complex that areefficient than incorporation of the VL chimeric envelopes
and was almost as efficient as the incorporation of the necessary for fusion triggering.
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Our data are therefore consistent with the hypothesis binding domain can be grafted to the N-terminus of the
trimeric adaptor polypeptide, it should be possible tothat the inhibitory effect of the RAM-1 binding domain, the
VL and II peptides, and of the C-terminal domain of the generate retroviral vectors whose attachment is targeted
to specific cell types, whereupon their infectivity can beCD40 ligand is a consequence of their ability to form a
trimeric complex at the tip of the SU trimer to which they activated by a specific membrane protease on the sur-
face of the target cell. In support of these suggestions,are grafted, and thereby to block the receptor binding
sites of the SU glycoprotein which are necessary for virus we have recently generated EGF-displaying retroviral
vectors whose infectivity on EGF receptor-positive cellsattachment. We previously demonstrated that a displayed
receptor-binding domain could inhibit retrovirus infectivity is activated by matrix metalloproteinases known to be
expressed abundantly at sites of cancer invasion, angio-by a different mechanism in a cell-type-specific manner.
In that study, we showed that a displayed monomeric EGF genesis, and inflammation (Peng et al., 1997).
In summary, our results demonstrate a novel mecha-domain could inhibit retroviral infectivity on EGF receptor-
expressing cells by competitively sequestering the engi- nism whereby a homotrimer-forming polypeptide fused to
the N-terminus of a retroviral envelope glycoprotein canneered vector particles onto the EGF receptors, which do
not support subsequent steps in virus entry. However, interfere with retroviral vector attachment and infectivity.
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